litlas
Log inCreate account

Robert G. Uzzo

Active 1991–2025

Also published as
Robert G. UZZO
178
Papers
29,045
Citations
92
h-index
169
i10-index

Citations

Citations per year for Robert G. Uzzo1986: 1 citations1992: 3 citations1993: 1 citations1996: 2 citations1997: 1 citations1998: 6 citations1999: 10 citations2000: 27 citations2001: 35 citations2002: 33 citations2003: 32 citations2004: 62 citations2005: 75 citations2006: 92 citations2007: 102 citations2008: 106 citations2009: 84 citations2010: 126 citations2011: 186 citations2012: 184 citations2013: 135 citations2014: 140 citations2015: 163 citations2016: 147 citations2017: 125 citations2018: 204 citations2019: 682 citations2020: 828 citations2021: 724 citations2022: 578 citations2023: 474 citations2024: 828 citations2025: 344 citations2026: 16 citations1987–1991: no citations, so these years are not shown1994–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,293 citing papers, 27.8% of this breakdownChina: 809 citing papers, 9.8% of this breakdownItaly: 617 citing papers, 7.5% of this breakdownUnited Kingdom: 432 citing papers, 5.3% of this breakdownGermany: 374 citing papers, 4.6% of this breakdownFrance: 364 citing papers, 4.4% of this breakdownCanada: 357 citing papers, 4.3% of this breakdownJapan: 249 citing papers, 3% of this breakdownNetherlands: 224 citing papers, 2.7% of this breakdownSpain: 221 citing papers, 2.7% of this breakdownAustralia: 180 citing papers, 2.2% of this breakdownBelgium: 156 citing papers, 1.9% of this breakdown
0%27.8%Other 23.8%

Institutions

Fields

  • Medicine74.5%
  • Biochemistry, Genetics and Molecular Biology13.7%
  • Immunology and Microbiology2.4%
  • Pharmacology, Toxicology and Pharmaceutics1.8%
  • Engineering1.7%
  • Nursing1.5%
  • Other4.4%

Topics

  • Renal cell carcinoma treatment13.8%
  • Bladder and Urothelial Cancer Treatments6.4%
  • Renal and related cancers4.8%
  • Cancer Immunotherapy and Biomarkers2.7%
  • Prostate Cancer Diagnosis and Treatment2.7%
  • Prostate Cancer Treatment and Research2.3%
  • Other67.3%

Coauthors

All papers

Open in search
  1. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I

    Authors: Steven C. Campbell, Peter E. Clark, Sam S. Chang, José A. Karam, Lesley Souter, Robert G. Uzzo - The Journal of Urology 2021 cited by 725

  2. The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth

    Authors: Alexander Kutikov, Robert G. Uzzo - The Journal of Urology 2009 cited by 2,374

  3. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies

    Authors: Peter Makhov, Shreyas Joshi, Pooja Ghatalia, Alexander Kutikov, Robert G. Uzzo, Vladimir Kolenko - Molecular Cancer Therapeutics 2018 cited by 565

  4. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

    Authors: Sumanta K. Pal, Robert G. Uzzo, José A. Karam, Viraj A. Master, Frede Donskov, Cristina Suárez, Laurence Albigès, Brian I. Rini, Yoshihiko Tomita, Ariel Galapo Kann, Giuseppe Procopio, Francesco Massari, Matthew R. Zibelman, I. Antonyan, Mahrukh Huseni, Debasmita Basu, Bo Ci, William Leung, Omara Khan, Sarita Dubey, Axel Bex - The Lancet 2022 cited by 230

  5. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II

    Authors: Steven C. Campbell, Robert G. Uzzo, José A. Karam, Sam S. Chang, Peter E. Clark, Lesley Souter - The Journal of Urology 2021 cited by 254

  6. Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work

    Authors: Steven R. Austin, Yu‐Ning Wong, Robert G. Uzzo, J. Robert Beck, Brian L. Egleston - Medical Care 2013 cited by 718

  7. Renal Mass and Localized Renal Cancer: AUA Guideline

    Authors: Steven C. Campbell, Robert G. Uzzo, Mohamad E. Allaf, Eric B Bass, Jeffrey A. Cadeddu, Anthony Chang, Peter E. Clark, Brian J. Davis, Ithaar Derweesh, Leo Giambarresi, Debra A. Gervais, Susie L. Hu, Brian R. Lane, Bradley C. Leibovich, Philip M. Pierorazio - The Journal of Urology 2017 cited by 1,240

  8. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

    Authors: Naomi B. Haas, Judith Manola, Robert G. Uzzo, Keith T. Flaherty, Christopher G. Wood, Christopher J. Kane, Michael A.S. Jewett, Janice P. Dutcher, Michael B. Atkins, Michael Pins, George Wilding, David Cella, Lynne I. Wagner, Surena F. Matin, Timothy M. Kuzel, Wade J. Sexton, Yu-Ning Wong, Toni K. Choueiri, Роберто Пили, Igor Puzanov, Manish Kohli, Walter M. Stadler, Michael A. Carducci, Robert Coomes, Robert S. DiPaola - The Lancet 2016 cited by 638

  9. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Authors: Merry Jennifer Markham, KERRI WACHTER, Neeraj Agarwal, Monica M. Bertagnolli, Susan M. Chang, William Dale, Catherine Diefenbach, Carlos Rodríguez‐Galindo, Daniel J. George, Timothy D. Gilligan, R. Donald Harvey, Melissa L. Johnson, Randall J. Kimple, Miriam A. Knoll, Noelle K. LoConte, Robert G. Maki, Jane Meisel, Jeffrey A. Meyerhardt, Nathan A. Pennell, Gabrielle B. Rocque, Michael S. Sabel, Richard L. Schilsky, Bryan J. Schneider, William D. Tap, Robert G. Uzzo, Shannon N. Westin - Journal of Clinical Oncology 2020 cited by 169

  10. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline

    Authors: Antonio Finelli, Nofisat Ismaila, Bill Bro, Jeremy C. Durack, Scott Eggener, Andrew Evans, Inderbir S. Gill, David L. Graham, William C. Huang, Michael A.S. Jewett, Sheron Latcha, William T. Lowrance, Mitchell H. Rosner, Bobby Shayegan, R. Houston Thompson, Robert G. Uzzo, Paul Russo - Journal of Clinical Oncology 2017 cited by 376

  11. Zinc and zinc transporters in prostate carcinogenesis

    Authors: Vladimir Kolenko, Ervin Teper, Alexander Kutikov, Robert G. Uzzo - Nature Reviews Urology 2013 cited by 184

  12. Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.

    Authors: Laurence Albigès, Axel Bex, Cristina Suárez, Robert G. Uzzo, Xiaobin Tang, Zoe J. Assaf, Sarita Dubey, Erik T. Goluboff, Corey Carter, Romain Banchereau, Mahrukh A Huseni, Sumanta K. Pal, Brian I. Rini - Journal of Clinical Oncology 2024 cited by 49

  13. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation

    Authors: Andres Correa, Opeyemi A. Jegede, Naomi B. Haas, Keith T. Flaherty, Michael R. Pins, Edward M. Messing, Judith Manola, Christopher G. Wood, Christopher J. Kane, Michael A.S. Jewett, Janice P. Dutcher, Robert S. DiPaola, Michael A. Carducci, Robert G. Uzzo - Journal of Clinical Oncology 2019 cited by 153

  14. Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial

    Authors: Chaitanya Divgi, Robert G. Uzzo, Constantine Gatsonis, Roman Bartz, Silke Treutner, Jian Q. Yu, David Chen, Jorge A. Carrasquillo, Steven M. Larson, Paul Bevan, Paul Russo - Journal of Clinical Oncology 2012 cited by 258

  15. Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence

    Authors: Janusz Franco‐Barraza, Ralph Francescone, Tiffany Luong, Neelima Shah, Raj Madhani, Gil Cukierman, Essel Dulaimi, Karthik Devarajan, Brian L. Egleston, Émmanuelle Nicolas, R. Katherine Alpaugh, Ruchi Malik, Robert G. Uzzo, John P. Hoffman, Erica A. Golemis, Edna Cukierman - eLife 2017 cited by 107

  16. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer

    Authors: Sonali M. Smith, KERRI WACHTER, Howard A. Burris, Richard L. Schilsky, Daniel J. George, Douglas E. Peterson, Melissa L. Johnson, Merry Jennifer Markham, Kathryn F. Mileham, Muhammad Shaalan Beg, Johanna C. Bendell, Robert Dreicer, Vicki L. Keedy, Randall J. Kimple, Miriam A. Knoll, Noelle K. LoConte, Helen Mackay, Jane Meisel, Timothy J. Moynihan, Daniel A. Mulrooney, Therese M. Mulvey, Olatoyosi Odenike, Nathan A. Pennell, Katherine E. Reeder‐Hayes, Cardinale B. Smith, Ryan J. Sullivan, Robert G. Uzzo - Journal of Clinical Oncology 2021 cited by 97

  17. Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma

    Authors: Robert A. Figlin, Nizar M. Tannir, Robert G. Uzzo, Scott S. Tykodi, David Y.T. Chen, Viraj A. Master, Anil Kapoor, Daniel A. Vaena, William T. Lowrance, Gennady Bratslavsky, Mark DeBenedette, Alicia Gamble, Ana Plachco, Marcus S. Norris, Joe Horvatinovich, Irina Y. Tcherepanova, Charles A. Nicolette, Christopher G. Wood - Clinical Cancer Research 2020 cited by 78

  18. Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon–degrading Bacteria Among Bladder Cancer Patients

    Authors: Laura Bukavina, Ilaha Isali, Rashida Ginwala, Mohit Sindhani, Adam Calaway, Diana Magee, Benjamin Miron, Andres Correa, Alexander Kutikov, Matthew R. Zibelman, Mahmoud A. Ghannoum, Mauricio Retuerto, Lee Ponsky, Sarah C. Markt, Robert G. Uzzo, Philip H. Abbosh - European Urology Oncology 2023 cited by 48

  19. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

    Authors: Mohamad E. Allaf, Se-Eun Kim, Viraj A. Master, David H. McDermott, Lauren C. Harshman, Suzanne Cole, Charles G. Drake, Sabina Signoretti, Mahmut Akgül, Nicholas Baniak, Elsa M. Li-Ning, Matthew B. Palmer, Hamid Emamekhoo, Nabil Adra, Hristos Z. Kaimakliotis, Yasser Ged, Phillip M. Pierorazio, E. Jason Abel, Mehmet Asım Bilen, Kenneth Ogan, Helen Moon, Krishna Ramaswamy, Eric A. Singer, Tina Mayer, Jay Lohrey, Vitaly Margulis, Jessie Gills, Scott E. Delacroix, Mark J. Waples, Andrew James, Peng Wang, Toni K. Choueiri, M. Dror Michaelson, Anil Kapoor, Daniel Y.C. Heng, Brian Shuch, Bradley C. Leibovich, Primo N. Lara, Judith Manola, Deborah Maskens, Dena Battle, Robert G. Uzzo, Gennady Bratslavsky, Naomi B. Haas, Michael A. Carducci - The Lancet Oncology 2024 cited by 82

  20. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)

    Authors: Wenxin Xu, Mäneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert G. Uzzo, Janice P. Dutcher, Robert S. DiPaola, Venkata Sabbisetti, Rupal S. Bhatt - Clinical Cancer Research 2021 cited by 45

  21. Guideline for Management of the Clinical T1 Renal Mass

    Authors: Steven C. Campbell, Andrew C. Novick, Arie S. Belldegrun, Michael L. Blute, George K. Chow, Ithaar Derweesh, Martha M. Faraday, Jihad Kaouk, Raymond J. Leveillee, Surena F. Matin, Paul Russo, Robert G. Uzzo - The Journal of Urology 2009 cited by 1,841

  22. Small renal masses progressing to metastases under active surveillance

    Authors: Marc C. Smaldone, Alexander Kutikov, Brian L. Egleston, Daniel Canter, Rosalia Viterbo, David Y.T. Chen, Michael A.S. Jewett, Richard E. Greenberg, Robert G. Uzzo - Cancer 2011 cited by 405

  23. A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy

    Authors: Tobias Klatte, Vincenzo Ficarra, Christian Gratzke, Jihad Kaouk, Alexander Kutikov, Veronica Macchi, Alexandre Mottrie, F. Porpiglia, James Porter, Craig Rogers, Paul Russo, R. Houston Thompson, Robert G. Uzzo, Christopher G. Wood, Inderbir S. Gill - European Urology 2015 cited by 286

  24. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial

    Authors: Тимур Митин, Daniel Hunt, William U. Shipley, Donald S. Kaufman, Robert G. Uzzo, Chin‐Lee Wu, Mark K. Buyyounouski, Howard M. Sandler, Anthony L. Zietman - The Lancet Oncology 2013 cited by 159